COL1A2 and epilepsy: Treatment with 250 mg/kg/day CBZ for 3 weeks, a dose equivalent to that used in treating epilepsy in human subjects taking into account species differences19 and to correct cartilage defects in the MCDS mouse,11, 12 did not significantly modify cortical or trabecular bone mass in either control or Col1a2+/p.G610C femora (Figure 1A–I; Table S1).